Filed by Mylan N.V. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rules 14a-12(b) and 14d-2(b) of the Securities Exchange Act of 1934

Subject Company: Perrigo Company plc Commission File No. 001-36353

Better health for a better worldTM CreatingMylan & SustainablePerrigo: Growth and Value JulyTransforming 2015 the Industry Legal Matters MylanIRISH N.VLAW.’s RESTRICTIONS (“Mylan”) offer for ON Perrigo CERT AINCompany INFORMA plc (“Perrigo”)TION is governed by the Irish Takeover Panel Act, 1997, Takeover Rules 2013 (the “Irish Takeover Rules”). Under the Irish Takeover Rules, Mylan consultmanagement their professionalis prohibited advisers. from discussing any material information or significant new opinions which have not been publicly announced. Any person interested in shares of Mylan or Perrigo is encouraged to TheRESPONSIBILITY directors of Mylan ST AacceptTEMENT responsibility for the information contained in this communication, save that the only responsibility accepted by the directors of Mylan in respect of the information in this beencommunication to ensure that relating such toinformation Perrigo, Perrigo’ has beens subsidiaries correctly and and fairly subsidiary reproduced undertakings, or presented the Perrigo(and no boardsteps haveof directors been taken and theby thepersons directors connected of Mylan with to them, verify which this information). has been compiled To the frombest ofpublished the knowledge sources, and has likelybelief ofto afthefect directors the import of Mylan of such (who information. have taken all reasonable care to ensure that such is the case) the information contained in this communication is in accordance with the facts and does not omit anything UnderDEALING the provisions DISCLOSURE of Rule REQUIREMENTS 8.3 of the Irish Takeover Rules, if any person is, or becomes, ‘interested’ (directly or indirectly) in, 1% or more of any class securities’)of ‘relevant mustsecurities’ be publicly of Perrigo disclosed or Mylan, by not all later ‘dealings’ than 3:30 in anypm (New‘relevant York securities’ time) on ofthe Perrigo ‘business’ or Mylan day following (including the by date means of the of relevantan option transaction. in respect of,This or requirementa derivative willreferenced continue to, until any suchthe date ‘relevant on which the deemed‘offer period’ to be aends. single If twoperson or morefor the persons purpose co- of operate Rule 8.3 on of the the basis Irish of T akeoverany agreement, Rules. either express or tacit, either oral or written, to acquire an ‘interest’ in ‘relevant securities’ of Perrigo or Mylan, they will be them,Under mustthe provisions also be disclosed of Rule by8.1 no of laterthe Irish than T12akeover noon (NewRules, Y allork ‘dealings’ time) on thein ‘relevant‘business’ securities’ day following of Perrigo the date by Mylanof the relevantor ‘relevant transaction. securities’ of Mylan by Perrigo, or by any party acting in concert with either of Panel’A disclosures website table, at www giving.irishtakeoverpanel.ie. details of the companies in whose ‘relevant securities’ ‘dealings’ should be disclosed, can be found on the Irish Takeover ‘interest’Interests inby securities virtue of arise,the ownership in summary or control, when aof person securities, has long or by economic virtue of exposure,any option whether in respect conditional of, or derivative or absolute, referenced to changes to, securities. in the price of securities. In particular, a person will be treated as having an underTerms Rulein quotation 8, please marks consult are the defined Irish Tinakeover the Irish Panel’ Takeovers website Rules, at wwwwhich.irishtakeoverpanel.ie can also be found on or the contact Irish T theakeover Irish TPanel’akeovers website. Panel on If youtelephone are in numberany doubt +353 as to1 678whether 9020 or or not fax you number are required +353 1 to678 disclose 9289. a dealing

Legal Matters InADDITIONAL connection with INFORMA Mylan’sTION proposed acquisition of Perrigo (the “Perrigo Proposal”), Mylan has filed certain materials with the Securities and Exchange MayCommission 5, 2015 (the(which “SEC”), Registration including, Statement among wasother amended materials, on a June Registration 19, 2015 Statement and has not on yet Form been S-4 declared (that includes effective, an theoffer “Registration to exchange/prospectus) Statement”) andon a Mylanpreliminary intends proxy to file statement with the on SEC Schedule a Tender 14A Of onfer May Statement 5, 2015 on (which Schedule preliminary TO and certain proxy statementother materials. was amended This communication on June 19, 2015, is not the intended “Preliminary to be, and Proxy is not, Statement”). a substitute In forconnection such filings with or the for Perrigo any other Proposal, FILEDdocument WITH that THEMylan SEC may CAREFULL file with theY SEC AND in IN connection THEIR ENTIRETY with the Perrigo (IF AND Proposal. WHEN INVEST THEYORS BECOME AND SECURITYHOLDERS AVAILABLE) BEFORE OF MAKING MYLAN AN AND INVESTMENT PERRIGO ARE DECISION URGED BECAUSETO READ THE THEY DOCUMENTS WILL wwwCONT.sec.govAIN IMPOR or by TdirectingANT INFORMA a requestTION to Mylan ABOUT at 724-514-1813 MYLAN, PERRIGO or investor [email protected]. THE PERRIGO PROPOSAL. Any materials Such filed documents by Mylan will with be the available SEC that free are of required charge through to be mailed the website to shareholders maintained of byPerrigo the SEC and/or at AMylan copy will of this also communication be mailed to such will shareholders. be available freeThis of communication charge at the following has been preparedwebsite: perrigotransaction.mylan.com.in accordance with U.S. securities Such law website, Irish lawis neither and the endorsed, Irish Takeover nor sponsored, Rules. nor affiliated with Perrigo or any of its PafARfiliates.TICIP PERRIGO®ANTS IN SOLICIT is a registeredATION trademark of L. Perrigo Company. deemedThis communication to be participants is not in a thesolicitation solicitation of a of proxy proxies from in anyconnection investor with or shareholder the Perrigo. HoweverProposal ,under Mylan the and rules certain of the of SEC.its directors, Information executive regarding officers Mylan’ and sother directors members and executiveof its management officers may and beemployees found in mayMylan be PreliminaryInc.’s Annual Proxy Report Statement. on Form These10-K fordocuments the fiscal can year be ended obtained December free of char31, 2014,ge from which the sourceswas filed indicated with the above. SEC on Additional March 2, information2015 and amended regarding on theApril interests 30, 2015, of these as well participants, as in the Registration which may, Statementin some cases, and thebe NON-SOLICITdifferent than thoseATION of Mylan’s shareholders generally, will also be included in the materials that Mylan intends to file with the SEC when they become available. securities,This communication (2) the solicitation is not intended of an of to,fer and or invitationdoes not, constituteto purchase or or form otherwise part of acquire,(1) any ofsubscribefer or invitation for, sell toor purchaseotherwise or dispose otherwise of any acquire, securities subscribe or (3) for the, tendersolicitation, exchange, of any sell vote or or otherwise approval dispose in any jurisdictionof any regulation.pursuant to Nothis of communicationfer of securities or shall otherwise, be made nor except will thereby means be any of acquisitiona prospectus or meeting disposition the requirementsof the securities of Sectionreferred 10to inof thisthe Securitiescommunication Act of in 1933, any jurisdictionas amended. in contravention of applicable law or

FURLegalTHER Matters INFORMATION otherwiseThe distribution forwarded, of this distributed communication or sent in in, certain into, or jurisdictions from any such may jurisdiction. be restricted Therefore, or affected persons by the wholaws receiveof such thisjurisdictions. communication Accordingly (including,, copies without of this limitation, communication nominees, are nottrustees being, and and custodians) must not be, and mailed are or anysubject such to jurisdiction. the laws of anyTo the such fullest jurisdiction extent permitted will need byto informapplicable themselves law, Mylan about, disclaims and observe, any responsibility any applicable or liabilityrestrictions for orthe requirements. violations of anyAny such failure restrictions to do so mayby any constitute person. a violation of the securities laws of AllTRADEMARK trademarks, tradeDISCLAIMER names, product names, graphics and logos of Mylan or any of its affiliates contained herein are trademarks, registered trademarks or trade dress of Mylan or such affiliate in the United names,States and/or product other names countries. or logos All is othernot intended trademarks, to imply trade, and names, should product not be names construed and logos to imply contained, a relationship herein are with, the orproperty endorsement of their or respective sponsorship owners. of Mylan The byuse such or display other partyof other. parties’ trademarks, trade

FORLegalW MattersARD-LOOKING STATEMENTS TThisransaction”) communication of Mylan contains Inc. and “forward-looking Abbott Laboratories’ statements.” non-U.S. Such developed forward-looking markets specialtystatements and may branded include, generics without business limitation, (the statements “EPD Business”), about the the Perrigo benefits Proposal, and syner Mylan’gies ofs acquisitionthe Perrigo (the Proposal “EPD or EPD businessTransaction, levels, future future opportunities earnings, planned for Mylan, activities, Perrigo, anticipated or the combined growth, company market opportunities, and products, strategies, and any other competition, statements and regarding other expectations Mylan’s, Perrigo’ and targetss, or forthe futurecombined periods. company’ Theses may future often operations, be identified anticipated by the use comparableof words such words. as “will,” Because “may forward-looking,” “could,” “should,” statements “would,” inherently “project,” involve “believe,” risks and “anticipate,” uncertainties, “expect,” actual “plan,”future results “estimate,” may dif“forecast,”fer materially “potential,” from those “intend,” expressed “continue,” or implied “tar get”by such and forward-lookingvariations of these statements. words or PerrigoFactors willthat couldcooperate cause with or contributeMylan and to whether such dif Mylanferences will include, be able but to consummateare not limited the to: of uncertaintiesfer and compulsory related acquisition,to the Perrigo whether Proposal, Mylan including shareholders as to the will timing provide of the the of requisitefer and compulsoryapprovals for acquisition, the Perrigo whether Proposal, approvalsthe possibility for the that of competingfer and compulsory offers will acquisition be made, theor bepossibility required, that as a the condition conditions to obtaining to the consummation regulatory approvals, of the offer to willaccept not conditions be satisfied, that and could the reducepossibility the anticipatedthat Mylan benefitswill be unable of the ofto ferobtain and regulatorycompulsory includingacquisition; but the not ability limited to tomeet changes expectations in healthcare regarding and thepharmaceutical accounting andlaws tax and treatments regulations of ain transaction the U.S. and relating abroad; to thethe integrationPerrigo Proposal of Perrigo and theand EPD the EPD Transaction; Business changes being more in relevant difficult, tax time-consuming, and other laws, or costly expectedthan expected; following operating the Perrigo costs, customerProposal andloss theand EPD business Transaction; disruption the (including, retention of without certain limitation, key employees difficulties of Perrigo in maintaining and the EPD relationships Business being with employees,difficult; the customers, possibility clients, that Mylan or suppliers) may be unable being greaterto achieve than Business;expected syner expectedgies andor tar operatinggeted future efficiencies financial in and connection operating with performance the Perrigo and Proposal results; andchallenges the EPD to T ourransaction business within and strategic the expected plans time-frames posed by the or recent at all unsolicitedand to successfully business integrate proposal Perrigo made by and Teva the EPD manufacture,Pharmaceutical market, Industries and/or Ltd. sell (“T products,eva”) to directlyacquire allor throughof our outstanding third parties, shares; notwithstanding the capacity the to factbring that new allegations products toof market,patent infringement(s) including but not have limited not been to where finally Mylan resolved uses by its the business courts judgment(i.e., an “at-risk and decides to condition,launch”); success results of operationsclinical trials and/or and ourcash ability flows; to the execute ability on to newprotect product intellectual opportunities; property the and scope, preserve timing, intellectual and outcome property of any rights; ongoing the ef legalfect of proceedings any changes and in thecustomer impact and of anysupplier such relationshipsproceedings onand financial customer Perrigo,purchasing or thepatterns; combined the ability company; to attract the inherent and retain challenges, key personnel; risks, andchanges costs in in third- identifying, party relationships; acquiring, and the integrating impact of complementarycompetition; changes or strategic in the acquisitions economic and of otherfinancial companies, conditions products of the businessesor assets and of inMylan, andachieving the providing anticipated of estimates synergies; of uncertainties financial measures, and matters in accordance beyond the with control accounting of management; principles and generally inherent accepted uncertainties in the Unitedinvolved States in the of estimates America and(“GAAP”) judgments and usedrelated in thestandards preparation or on ofan financialadjusted statements,basis. For onmore Form detailed 10-Q information for the quarter on theended risks March and uncertainties31, 2015 and associated our other filingswith Mylan’ with thes business SEC. These activities, risks, seeas well the risksas other described risks associated in Mylan’ withs Quarterly Mylan, Report Perrigo, and the combined company are also more fully Exceptdiscussed as inrequired the Registration by applicable Statement law, Mylan and the undertakes Preliminary no obligationProxy Statement. to update You any can statements access Mylan’ hereins forfilings revisions with the or SECchanges through after thethe SECdate ofwebsite this communication. at www.sec.gov, and Mylan strongly encourages you to do so.

Legal Matters ThisNON-GAAP communication FINANCIAL includes MEASURES the presentation and discussion of certain financial information that differs from what is reported under GAAP. These non- GAAP financial measures, including, but not limited to, internallyadjusted diluted for forecasting, earnings perbudgeting share (“EPS”), and measuring are presented its operating in order performance. to supplement In addition,investors’ primarily and other due readers’ to acquisitions, understanding Mylan and believes assessment that anof evaluationMylan’s financial of its ongoing performance. operations Management (and comparisons uses these of measures its thecurrent last operationsslide of this with presentation, historical Mylanand future has operations)provided reconciliations would be dif ficultof such if thenon- disclosure GAAP financial of its financial measures results to the were most limited directly to comparablefinancial measures GAAP preparedfinancial onlymeasures. in accordance Investors with and GAAPother readers. Also, setare forth on non-GAAPencouraged measuresto review onlythe related as supplements GAAP financial to, not asmeasures substitutes and forthe orreconciliations as superior measures of the non-GAAP to, the measures measures of financialto their most performance directly comparableprepared in GAAPaccordance measures, with GAAP and investors. and other readers should consider TNOo the PROFIT extent FORECASTthat the Mylan / ASSET quarterly V ALUAresultsTIONS and/or the calendar year 2015 guidance contained or summarized in this communication constitute a profit forecast for the purposes of Rule 28 of the Irish Takeover statementRules, such in resultsthis communication and/or guidance is intendedwill (unless to constitute the Irish Taakeover profit forecast Panel consents for any periodotherwise) nor should be reported any statements on in accordance be interpreted with that to rulemean at that the earningsappropriate or earningstime. Except per share as described will necessarily in the previous be greater sentence, or less no SYNERGYthan those for ST theATEMENT relevant preceding financial periods for Mylan or Perrigo as appropriate. No statement in this communication constitutes an asset valuation. SynerTheregy are Statement various material being materially assumptions greater underlying or less thanthe statement estimated. relating The Syner to “atgy least Statement $800 millionshould thereforeof annual bepre-tax read inoperational conjunction syner withgies” the (thekey “Synerassumptionsgy Statement”), underlying which such estimatesmay result which in the are value set inout the in TheMylan’ Syners announcementgy Statement pursuantshould not to be Rule construed 2.5 of the as aIrish profit Takeover forecast Rules or interpreted on April 24,to mean 2015 that (the the “2.5 combined Announcement”). earnings of Mylan and Perrigo in any period following this communication would necessarily match Theor be Syner greatergy thanStatement or be lesshas beenthan thosereported of Mylanon for and/orthe purposes Perrigo of for Rule the 19.3(b)(ii) relevant preceding of the Irish financial Takeover period Rules or byany (i) other the Irish period. firm of AnnouncementPricewaterhouseCoopers and (ii) Goldman Sachs International. Copies of their respective reports are included in Appendix IV and Appendix V to the 2.5

•Agenda Creating Sustainable Growth and Value with Perrigo • NoA Compelling Clear Pathway Offer for Teva’s Hostile Strategy

TheMylan combination + Perrigo of Mylan and Perrigo demonstrates clear and compelling •industrial Generates logic significant value for customers, patients, employees, stockholders and other stakeholders Ø• Creates Complementary a one-of-a-kind businesses global and healthcare cultures company that has: Ø OneUnmatched of the industry’ scale in sits broadest operations and most diversified portfolios •Ø This Immense unique reach infrastructure across distribution will be able channels to maximize around evolving the world industry dynamics and capitalize on key trends, including the unprecedented number of Rx to OTC switches underway

Why is Perrigo the Right Next Strategic GrowthTransaction? focused acquisition where 1 + 1 = > 3 ü One-of-a-kindHorizontally integrates profile within Mylan’ thes operationsindustry into new categories, creating platform for long-term growth ü Mylan’Unmatcheds European quality ,platform scale and can flexibility dramatically expand Perrigo’s Omega Allowsü Outstanding Mylan R&Dto offer platform customers a complete suite of products (Gx, OTC, & Rx) DeliversAbility to reliability capitalize and on evolvingcost advantages industry to dynamics customers ExtensivePotential to combined superchar technologyge growth andbase expansion and pipeline

Focused$800m in and Syner Verygies Achievable are Largely Operationally PerrigoCore Syner Combinationgy Categories Rationale SalesManufacturing operations ü üHighly Same similarcustomers facilities ResearchDistribution and ü DevelopmentSame delivery ü pointOverlapping R&D operations and more efficient product development DivestituresAdministrative ü Likely ü Ability limited to further streamline operations estimateØ Potential of atfor least meaningful US $800m revenue of annual syner pre-taxgies beyond operational what is syner includedgies in Mylan’s • DeeperCross selling customer products relationships Ø• Leveraging R&D operations Mylan’ ares global complementary footprint Mylan has Driven Outstanding Shareholder AdjustedReturns by diluted Looking EPS Y growth1ears Ahead and Executing EPS2008-2015 Growth adjusted = 27% dilutedCAGR $2.04$1.61 $2.89$2.59 $4.15$3.56 2008$0.80 2009 $1.30 2010 2011 2012 2013 2014 2015 Non-USGenerics developedand specialty markets pharmaceutical specialty and business branded generics business 20152007 2010 2012 2015 Next CAGRs1. Source: calculated Mylan prospectus based on 2008supplement – 2015 datedguidance 30-Mar mid-point-2015. Note:data. Adjusted *2008 and diluted 2009 EPSrepresent is a non-GAAP total adjusted financial revenue. measure. Note: **2015 figures represent the mid-point of 2015 financial guidance ranges. Note: All

25xImplied Blended P/E Multiple Over Time MylanAverage 13 x Perrigo 18 x Blended 16 x 20xMylan / Perrigo 15x18x 12x15x 5x10x DailyJan-14 from Jun-14 02-Jan-2014 Nov-14 Apr to -1502-Apr-2015 Source:Mylan Perrigo Bloomber Blendedg and P/EIBES estimates as of 02-Apr-2015 • Creating Sustainable Growth and Value with Perrigo • NoA Compelling Clear Pathway Offer for Teva’s Hostile Strategy

Mylan’s Compelling Offer for Perrigo • Legally$75 in cash binding plus under2.3 Mylan Irish sharesTakeover for Ruleseach Perrigo with committed share financing in place • MylanExpected has to made maintain a “hell investment or high water” grade commitmentstatus to obtain HSR clearance • OnceOffer thefully Mylan values shareholder Perrigo with vote a takeover is completed, premium it will based not beon possiblepublic information to materially change the consideration in the offer without an additional shareholder vote How Does the Street Value Mylan’s Offer for Perrigo? …ButPerrigo the Claims Market March Showed 10 is Us Their View Unaffected Price… Mylan$73 Announced Share Price 8-Apr on 10-Mar-2015 -2015 $ 55.31 Transaction $68.36 (USDMylan ) Share $68 +15% Price on 8-Apr-2015 $ 68.36 PricImplied e $63 Perrigo Offer $ 202.20 Implied Perrigo Offer $ 232.23 6-AprImplied 7-Apr Perrigo 8-Apr Enterprise Value1 $ 33,878 g $58 Implied Perrigo Enterprise Value1 $ 38,307 Implied 2014A EBITDA Multiple 22x Closin $53 Implied 2014A EBITDA Multiple 25x 3Implied Deal Value Based on Analyst Price Targets Selected Precedent Transactions for Mylan Pro Forma with Perrigo2 5-Feb-15Size LTM Pfizer Date T/ ransactionHospira $17 ($bn) 23x EV / EBITDA Source Leerink RBC Bernstein, UBS, JPM DB 17-Nov-14Mylan Share Actavis Price $80 / Aller $79gan $75 $66 $70 28x 6-May-14Implied Total Bayer Value / Merck of Of (Consumerfer $259 $257 Care) $248 $14 $236 21x Source:Implied Bloomber2014A EBITDAg, Company Multiple Filings 28x and28x W 27xall 26xStreet research 21 TheEnterprise information Values on in this millions page ofis baseddollars. on targets provided by various analysts. The information is not intended to constitute a profit forecast for any period, nor should it be interpreted to mean that earnings or MYL,”earnings 9-April-2015; per share will RBC, necessarily “Further be Thoughts,”greater or lesser 10-April-2015; than those Bernstein,for the relevant “Not precedingMuch Enthusiasm financial Out periods There,” for Mylan23-April-2015; or Perrigo UBS, as appropriate. “Joe Likely Sources to Just Sayinclude: No,” Leerink, 9-April-2015; “Win-W JPin Mor Scenariosgan, “MYL in front PRGO of Offer 3Moves JPM assumesForward,” midpoint 24-April-2015; of “mid-70’ Deutsches” price Bank, target. “Teva-MYL Still Case to Beat,” 24-April-2015. 15 Process to Completion 50%+1• Mylan majority shareholder vote vote required, expected with in a Augustquorum of at least 1/3 of the issued shares Abbott has publicly stated it will vote its 14.2%1 in favor of the deal • AfterRegulatory receiving clearance Mylan process shareholder is already approval, underway Mylan will make a tender offer to Perrigo shareholders •T enderCustomary offer closingconditions expected for an inof ferOctober/November governed by the Irish Takeover Rules 161 Ownership calculated using 490.03mm Mylan basic shares outstanding with 69.75mm shares held by Abbott.

• Creating Sustainable Growth and Value with Perrigo • NoA Compelling Clear Pathway Offer for Teva’s Hostile Strategy A Teva + Mylan Combination Lacks Strategy and Growth PortfolioProduct DivestituresHigh degree Massive,of overlap including in both marketed around Copaxone® products and and pipeline Epipen® franchises CustomersTechnologies Of fersNo new no solution platform for for customers’ growth from changing combination needs ØGrowth Cost synergies provide short-term benefit at the expense of long-term growth Ø MajorKey growth business drivers disruption for both through companies difficult will integration need to be divested Ø 1No + new1 = 1.5 business model coming from combination

No Clear Path for Teva’s Hostile Strategy CanCritical Teva Question fully acquire Answer Mylan without Board Squeeze-out is the only option to get to 100% and requires cooperation? 95% ownership management,Can Teva gain 95% ownership? No, Abbott contractually prohibited from selling ~14.2%1 stake directly to Teva Can Teva gain synergies or cash flow from No, Teva must have control of Mylan’s Board, CanMylan Teva without control a full Mylan’ acquisition?s Board, andmanagement operations No, requires replacement of Mylan’s directors or operations prohibitsCan Teva Tcalleva a from vote? nominating Board can directorsinvoke response No, removal time of updirectors to 180 requiresdays in face2/3 majorityof proposed of shares, vote on representing Board dismissal more /than change 50% in of strategy the total Can share Teva capital; replace and, Mylan’ even sif directors? all directors No, are binding removed, nomination Chairman process can cannotappoint force new directorsMylan to Candivest Teva its owndo “hell products or high without water” control to secure of Mylan’No, nots unlessBoard, willing management, to divest and Copaxone®. operations Any divestitures, antitrust clearance? including Copaxone®, must come from Teva, since Teva InDoes sum, Teva 4.61% have ownership a clear path? allows No, T andeva theyto bring could a suit,spend but years has noproving bearing it on winning it 191 Ownership calculated using 490.03mm Mylan basic shares outstanding with 69.75mm shares held by Abbott. Appendix

(Unaudited;Reconciliation USD of Non-GAAPin millions) YMetricsear Ended December 31, GAAP2014 2013 income 2012 tax 201 expense1 2010 (benefit)2009 2008 $121$41 $1$16116 $(21)$10 T$129ax effect of adjustments to pre-tax income and other income tax related items (260)(432) (198)(216) (273)(253) Adjusted(31) income tax expense $381$473 $314$377 $252$263 GAAP$160 (earnings) loss attributable to the noncontrolling interest $(3)$(4) $—$(2) $(15)$— Restructuring$4 and other special items — — 10— Adjusted— (earnings) loss attributable to the noncontrolling interest $(3)$(4) $—$(2) $(5)$— Adjusted$4 pre-tax income $1,523$1,893 $1,208$1,466 $840$970 Adjusted$539 income tax expense (381)(473) (314)(377) (252)(263) Less:(160) —Preferred Dividend — — (139)— (4)Adjusted (earnings) loss attributable to the noncontrolling interest (2)(3) —(1) 4(5) $1,416 Adjusted net income $1,087$1,139 $707$893 $244$583 398Diluted shares 420394 313439 304307 —Add: If-converted shares — 125— —143 398 Adjusted diluted shares 420394 438439 304450 $3.56Adjusted diluted earnings per share $2.59$2.89 $1.61$2.04 $0.80$1.30